LB0001 Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study.

2018

https://researcherprofiles.org/profile/79292878

D. van der Heijde, L.S. Gensler, A. Deodhar, X. Baraliakos, D. Poddubnyy, M.K. Farmer, D. Baeten, T. Kumke, M. Oortgiesen, M. Dougados